Tel: 961 4 930252 - Email: info@pheniciagroup.com

Normon S.A. - Spain

BISOPROLOL NORMON
Cinitrex
ESCITALOPRAM NORMON
ESLORAT
ESOMEPRAZOLE NORMON
ESTECINA Inj.
ESTECINA Tablets
FIXIM
GASTRIMUT
LAMOTRIGINE NORMON
LEVOFLOXACIN NORMON
LIDOCAINE 2% EPINEPHRINE NORMON
NORMOCEF
Normocoxib
NORMOPRIL
PARACETAMOL NORMON
SIMVASTATIN NORMON
TOPAGAN
Forms and presentation
Tablets: Box of 50.
 
Composition
Each tablet contains: Cinitapride: 1 mg.
 
Properties
Cinitrex belongs to a group of medicines called prokinetics, which are gastrointestinal motility stimulants.
 
Indications
Cinitrext is indicated to treat gastroesophageal reflux to enhance the effect of proton-pump inhibitors and mild-moderate functional gastrointestinal motility disorders.
 
Contraindications
-If you are allergic to cinitapride or any other ingredient of cinitrex.
-If you have gastrointestinal bleeding, obstruction or perforation.
-If you have a history of neuroleptic-induced tardive dyskinesia.
 
Precautions
Talk to your doctor or pharmacist before you start taking Cinitrex if you are an elderly patient and you have to take this medicinal product for a prolonged period of time.
 
Drug interactions
Cinitrex may decrease the effect of digoxin.
 
Cinitrex with food, drink and alcohol
Cinitrex should not be taken with alcohol since it enhances the sedative effects.
 
Ability to drive and use machine
Do not drive or use dangerous machinery during treatment with cinitrex.
 
Pregnancy 
Cinitrex should not be administered during the first trimester of pregnancy.
 
Possible adverse effects
Some patients may notice a slight sedation or somnolence.
On very rare occasions skin reactions may occur, such as rash, itch and very occasionally angioedema.
 
Dosage and administration
Usual dose for adults (over 20 years old) is 1 tablet, 3 times a day, 15 minutes before meals.
 
Overdosage
Consult your doctor, pharmacist or go to the hospital and take your medicines with you.
 
 
 
Origin: Spain
Laboratories: Normon S.A
Distributor: Droguerie Phenicia
Number of Registration : 1017/1